Tomasi Adam 4

4 · Allakos Inc. · Filed May 15, 2025

Form 4

Period: 2025-05-15

President

Transactions

Disposition to Issuer
Common Stock
2025-05-15−512,630→ 0 total
Disposition to Issuer
Stock Option (right to buy)
2025-05-15−486,400→ 0 total
Exercise: $0.69Exp: 2027-05-17→ Common Stock (486,400 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-05-15−145,011→ 0 total
Exercise: $4.01Exp: 2028-01-27→ Common Stock (145,011 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-05-15−88,036→ 0 total
Exercise: $4.31Exp: 2028-05-15→ Common Stock (88,036 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-05-15−300,471→ 0 total
Exercise: $7.20Exp: 2033-01-06→ Common Stock (300,471 underlying)
Disposition to Issuer
Common Stock
2025-05-15−20,790→ 0 total(indirect: See footnote)
Disposition to Issuer
Stock Option (right to buy)
2025-05-15−125,000→ 0 total
Exercise: $35.28Exp: 2028-10-09→ Common Stock (125,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-05-15−1,200,000→ 0 total
Exercise: $1.25Exp: 2034-02-16→ Common Stock (1,200,000 underlying)

Footnotes (4)

[F1]Includes 190,270 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.
[F2]Disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. (the "Merger Agreement") in exchange for $0.33 in cash per share.
[F3]The shares are held by Mr. Tomasi and Carrie Tomasi, as Trustees of the Tomasi Living Trust dated July 14, 2017.
[F4]This option was cancelled without consideration pursuant to the terms of the Merger Agreement.

Documents

1 file